REGENXBIO Inc. (RGNX) stock
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
REGENXBIO Inc. grew revenue 12.0% to $174.48M over the twelve months to Jun 30, 2026. Free cash flow was -$249.67M. At the latest close the market valued the company at $477.94M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $477.94M
- P/E ratio
- –
- Price to sales
- 2.74
- Price to book
- 6.66
- Dividend yield
- –
- Free cash flow yield
- -52.24%
Fundamentals
- Revenue
- $174.48M
- Net income
- -$196.43M
- EPS, diluted
- -$3.79
- Free cash flow
- -$249.67M
- Book value per share
- $1.35
- Diluted shares
- 53M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $7.32
- Open
- $7.35
- Day's range
- $6.83 – $7.49
- Volume
- 963,089
- Average volume (20 days)
- 1,251,358
- Index membership
- Russell 2000, Russell 3000
- 52-week range
- $5.46 – $16.19
- RSI (14 days)
- 45.8
- Volatility (1 year)
- 92.7%
- Relative volume
- 0.67×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | RGNX | S&P 500 | Difference | RGNX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.5% | -4.0% | +8.6 pts | ||
| 3 months | -36.1% | -5.0% | −31.1 pts | ||
| Year to date | -49.7% | +8.2% | −58.0 pts | ||
| 1 year | -35.0% | +11.2% | −46.2 pts | ||
| 3 years | -62.9% | +68.5% | −131.3 pts | -28.1% | +19.0% |
| 5 years | -77.0% | +67.3% | −144.3 pts | -25.5% | +10.8% |
| 10 years | -67.8% | +291.6% | −359.5 pts | -10.7% | +14.6% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Regenxbio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- News
- Results
About Regenxbio
Biological Products, (No Diagnostic Substances)
REGENXBIO Inc. is a clinical-stage biotechnology company that focuses on the development and commercialization of gene therapies. The company utilizes its proprietary NAV Technology Platform to deliver genetic medicines for severe conditions. Its pipeline includes surabgene lomparvovec, RGX-121, and RGX-111, which are evaluated across clinical studies such as AAVIATE, ALTITUDE, and ATMOSPHERE. REGENXBIO provides development services, licensing rights, and technology access to partners. Its customers and collaborators primarily consist of global pharmaceutical and biotechnology companies, such as AbbVie and Nippon Shinyaku, as well as research institutions.
Company profile, executives and historyRegenxbio stock: common questions
What is Regenxbio's stock price?
RGNX closed at $7.24 on Nov 17, 2026, down 1.09% on the day. Over the past 52 weeks it traded between $5.46 and $16.19.
What is Regenxbio's market cap?
Regenxbio was worth $477.94M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is RGNX's P/E ratio?
Regenxbio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.79), so it has no meaningful P/E ratio.
How much revenue does Regenxbio make?
Regenxbio reported revenue of $174.48M for the twelve months to Jun 30, 2026, up 12.0% from a year earlier.
Does Regenxbio pay a dividend?
No. Regenxbio has not paid a cash dividend over the last twelve months.
When does Regenxbio report earnings next?
Regenxbio is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RGNX stock performed over the past year?
Including dividends, RGNX returned -35.0% over the past year, against +11.2% for the S&P 500.
How many RGNX shares are sold short?
10M shares were sold short at the latest FINRA report, 16.69% of the float, or 8.3 days of average trading volume.
Who are Regenxbio's competitors?
Companies most similar to Regenxbio by business, industry and size include AGEN, FDMT, ALEC, BEAM, MGTX.
See a number that looks wrong?